Vivos Therapeutics, Inc. Balance Sheet
VVOS|6 years of annual SEC 10-K data (FY2020-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 6 fiscal years. All figures from audited SEC 10-K filings.
Vivos Therapeutics, Inc. had $25M in total assets with negative shareholders' equity of $1M as of FY2025. Total debt was $753,000 against $2M in cash, resulting in a $1M net cash position.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.20 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.0M | $6.3M | $3.5M | $3.5M | $24.0M | $18.2M |
| Accounts Receivable | $1.6M | $430.0K | $457.0K | $457.0K | $1.2M | $1.4M |
| Current Assets | $4.4M | $7.5M | $5.4M | $5.4M | $27.3M | $20.4M |
| PP&E (Net) | $3.8M | $3.4M | $3.1M | $3.1M | $2.8M | $871.6K |
| Goodwill | $8.6M | $2.8M | $2.8M | $2.8M | $2.8M | $2.7M |
| Total Assets | $25.2M | $15.3M | $13.7M | $13.7M | $33.7M | $25.3M |
| Current Liabilities | $18.1M | $5.0M | $6.8M | $6.8M | $7.5M | $7.8M |
| Total Debt | $753.0K | - | - | - | - | $1.3M |
| Shareholders' Equity | -$1.5M | $411.0K | $25.5M | $25.5M | $16.9M | -$2.9M |